

AF/1641  
AP

## TRANSMITTAL OF APPEAL BRIEF (Large Entity)

Docket No.  
PU0124  
JFWIn Re Application Of: **Ronnie Palmgren**

Application No. 09/863,786	Filing Date May 23, 2001	Examiner Deborah A. Davis	Customer No. 22840	Group Art Unit 1641	Confirmation No. 2351
-------------------------------	-----------------------------	------------------------------	-----------------------	------------------------	--------------------------

Invention: **Peptide Fragmentation**COMMISSIONER FOR PATENTS:

Transmitted herewith in triplicate is the Appeal Brief in this application, with respect to the Notice of Appeal filed on  
September 6, 2005.

The fee for filing this Appeal Brief is: **\$500.00**

- A check in the amount of the fee is enclosed.
- The Director has already been authorized to charge fees in this application to a Deposit Account.
- The Director is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **502-590**
- Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

Signature  
Dated: **October 26, 2005**

Royal N. Ronning, Jr.  
Amersham Biosciences Corp  
Patent Department  
800 Centennial Avenue  
Piscataway, NJ 08855

(732) 457-8423  
Reg. No.: 32,529

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

October 26, 2005

(Date)

*Signature of Person Mailing Correspondence*

**Melissa Leck**

*Typed or Printed Name of Person Mailing Correspondence*

cc:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES**

Appl. No. : 09/863,786 Confirmation No.: 2351  
Applicant : Ronnie Palmgren  
Filed : May 23, 2001  
TC/A.U. : 1641  
Examiner : Deborah A. Davis  
  
Docket No. : PU0124  
Customer No. : 22840

Mail Stop Appeal Brief – Patents  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

October 26, 2005

**APPEAL BRIEF**

Sir:

Appellant submits this Appeal Brief in triplicate, appealing from the June 1, 2005, rejection of the Primary Examiner, finally rejecting claims 1–12 and 15–20, in the captioned application. The Notice of Appeal was filed on September 6, 2005, which contained authorization to charge the “Appeal Fee” to Appellant’s Deposit Account. Filed concurrently herewith is the “Transmittal of Appeal Brief (Large Entity)”, in duplicate, which contains authorization to charge the fee for filing the Appeal Brief to Appellant’s Deposit Account.

10/31/2005 BABRAHAI 00000083 502590 09863786

01 FC:1402 500.00 DA

### **Real Party in Interest**

Amersham Biosciences AB, formerly known as Amersham Pharmacia Biotech AB, is the assignee and owner of the captioned application, is the real party in interest to this appeal.

### **Related Appeals and Interferences**

There are no other appeals or interferences related to the instant appeal.

### **Status of Claims**

Claims 1–12 and 15–20 are pending in the captioned application. These are the only pending claims subject to examination before the U.S. Patent and Trademark Office. A copy of these claims is appended hereto.

### **Status of Amendments**

There are no outstanding amendments with regard to the captioned application. However, Appellant has submitted proof of the abandonment of copending patent application number 10/478,910, and thus has obviated the Examiner's grounds for the obviousness-type double patenting rejection. This rejection is not addressed in the instant Appeal.

### **Summary of Claimed Subject Matter**

The instant invention relates to methodology and reagents for use in identification of peptides or polypeptide using mass spectrometric technique, which reagents are more

environmentally acceptable than prior use of organic solvents. The reagents include a novel class of water-stable derivatization reagents, which include a sulfonyl moiety coupled to an activated acid moiety, to provide peptide derivatives for analysis in subsequent mass spectrometry steps. The invention further provides a simplified and easily automated procedure for derivatizing peptides or polypeptides prior to such identification (page 3, lines 5–15).

The methodology for identification of peptides or polypeptides comprises the steps of: (a) derivatization in an aqueous solution the N-terminus of the polypeptide, or the N-termini of one or more peptides of the polypeptide, with at least one acidic reagent comprising a sulfonyl moiety coupled to an activated acid moiety to provide one or more peptide derivatives, which reagent exhibits a half-life in aqueous solution of not less than 10 minutes, preferably not less than about 20 minutes and most preferably not less than about 30 minutes at room temperature; (b) analyzing at least one such derivative using a mass spectrometric technique to provide a fragmentation pattern; and (c) interpreting the fragmentation pattern obtained (page 3, lines 15–26).

Independent claim 1 recites this as the above-referenced method; claims 2–12 which are directly or ultimately dependent on claim 1, further define properties of the acidic reagent (see claim 2 and page 10, line 19); claims 3 and 4 recite particular mass spectrometric techniques which can be utilized (see e.g., page 8, line 6); claims 5 and 6 recite specific automation use in the process (see e.g., page 10, line 1–10); claims 7 to 9 define suitable activated acid moieties (see e.g., page 10, line 25 to page 11, line 5)

and claims 10 to 12 define methodology for obtaining the peptides and peptides of interest (see e.g., page 14, line 9 to page 15, line 20). Further claim 15 defines a kit useful for the methodology (see e.g., page 16, line 5 –10) and claims 16 to 20 recite the kit containing the limitations of claims 2 to 9 described supra.

### **Grounds of Rejection to be Reviewed on Appeal**

1. Whether claims 1–6, 10–13 and 15–18 are properly rejected under 35 U.S.C. § 102(a) as being anticipated by Keough, et al (WO 00/43792).
2. Whether claims 7–9 and 19 are properly rejected under 35 U.S.C. § 103(a) as being unpatentable over Keough, et al in view of Little et al (USP 6,322,970).

### **Argument**

1. **Claims 1–6 and 10–13 and 15–18 are not properly rejected under 35 U.S.C. § 102(a) as being anticipated by Keough, et al (WO 00/43792).**

The Examiner has rejected claims 1–6, 10–13 and 15–18 under 35 U.S.C. § 102(a) as “being anticipated by Keough et al (WO 00/43792)”.

Specifically, the Examiner stated, “Keough et al anticipates the instant invention by teaching a method of identifying a polypeptide by derivatizing the N-termini of one or more peptides with one or more acidic moieties having a pKas of less than about 2 when coupled with the polypeptide or peptide to provide one or more derivatized analytes. This method is analyzed by mass spectrometric techniques to provide a fragmentation pattern (summary)”.

The Examiner continued, “the fragmentation pattern of the peptide is interpreted to sequence the polypeptide (page 7, lines 1-2). Thomas et al discloses coupling an acidic moiety reagent to the N-terminus of a cysteine-containing peptide, followed by oxidation to produce peptides containing two acidic moieties (sulfonic acids). The preferred acidic moieties are 2-sulfoacetyl, 2-sulfobenzoyl and 3-sulfolpropionyl moieties (page 9, lines 1-15). These preferred acidic moieties are sulfonyls coupled to an ester moiety such as sulfosuccinic anhydride, and 2-sulfobenzoic acid cyclic anhydride and others (page 9, lines 1-30)”.

The Examiner conceded, “Keough et al is silent with respect to the half-life of the acid reagent not being less than 10 minutes, however, it is the Examiner’s position that this teaching is inherent to what the instant reference teaches. Keough et al teaches the acid reagents utilized in the instant invention, therefore these reagents will inherently exhibit a half-life in aqueous solution of not less than 10 minutes”.

In response, Appellant respectfully reiterated the arguments that the recited acidic reagent contains “a sulfonyl moiety coupled to an ester moiety”; such is neither taught, nor even suggested, by the Keough, et al. reference. While Appellant conceded that Keough, et al. does teach coupling of sulfonyls to anhydride reagents, Appellant asserted that anhydrides are not esters. The benefits of use of the reagents of the instant invention are disclosed at pages 8-11 of the captioned application, and include aqueous stability. Indeed, as stated at page 9, lines 5-11, one of the advantages of the instant invention

compared to the disclosure of the Keough, et al. reference “resides in the fact that according to the present invention all steps can be carried out under aqueous conditions. As previously suggested technology required to dry-down steps and several small pH changes from basic to acidic, and vice versa, the present method is much more amenable to automation”.

In response to this argument, the Examiner stated, “although the anhydride reagents recited by Keough are not esters; a sulfonyl group coupled to an ester is found within the 3-sulfopropionic anhydride structures, (see example 8, page 14) and as evidenced by Appellant’s instant specification on page 23 which describes the synthesis of a NHS ester from a 3-sulfopropionic anhydride. Although the reference of Keough et al did not synthesize an NHS ester from 3-sulfopropionic anhydride, it is apparent that an ester coupled to a sulfonyl group is within the structure of the 3-sulfopropionic anhydride. The instant claim 1 calls for at least one acidic reagent containing a sulfonyl moiety coupled to an ester moiety, therefore, Keough satisfies the limitation of claim 1”.

In response, Appellant pointed out that the compound disclosed at page 14, example 8 of the Keough, et al. reference is 3-sulfopropionic anhydride. Even if Appellant were to accept the Examiner’s contention that this compound embodies “a reagent containing a sulfonyl moiety coupled to an ester moiety”, which Appellant did not concede, anhydrides are very sensitive to water and would not exhibit the half-life recited in the claim “a half-life in aqueous solution of not less than 10 minutes at room temperature”. Indeed, as stated at page 24, lines 23–25 of the captioned application, 3-

sulfopropionic anhydride “was very sensitive to water and it was necessary to dry all equipment in an oven before use and to do the reaction and purification under an argon atmosphere”.

Further, at page 3, lines 5–10 of the captioned application, it is stated that one objective of the instant invention is achieved by “using a novel class of water-stable derivatization reagents, which comprise a sulfonyl moiety coupled to an activated acid moiety”. Thus, the water stability recited in the claim is an inherent characteristic of the reagents used in the methodology of the instant invention. Such water stability is neither disclosed nor even suggested by the Keough, et al. reference.

As for the Examiner’s statement regarding Appellant’s assertion that all the steps can be carried out under aqueous conditions making it amenable to automation, versus the previous technology which requires dry-down steps and stated, “This assertion is noted but not found persuasive because these benefits are not found in the claims”, Appellant respectfully directs the Examiner’s attention to the statement in claim 1(a), which states that the reagent exhibits “a half-life in aqueous solution...” Such benefits are clearly a result of this stability in aqueous solution.

In response to these arguments, the Examiner directed Appellant’s attention to “the examples on page 12, example 6”, and suggested that Appellant “compare it with applicant’s example in the specification on page 23”. The Examiner continued, “This reagent is not an anhydride; it has a sulfonyl group with an ester group attached, and

therefore it would appear that this reagent would have the same benefits as the aqueous stability as recited in the instant claim 1”.

In response, Appellant respectfully points out that the reagent in Example 6, i.e., the material (which is recited with the peptide) does not include “a sulfonyl moiety coupled to an ester moiety” as recited in instant claim 1. Specifically, Appellant respectfully asserts that such is critical to the instant invention since the purpose of the sulfonyl moiety permits stabilization of an acidic moiety with the desired pKa value while having a desirable half-life in the solution. While the ultimate reacted product contains a peptide coupled to an organic chain including a sulfonyl moiety, it is obtained by quite different means. Indeed, as stated at page 13, after the reaction, the sample is “desalted and oxidized with 10  $\mu$ L of formic acid (88%):H2O2 (30%) prepared at a ratio of 19:1 (v:v). Oxidation proceeds for 30 minutes at room temperature, and the derivatized analyte is dried prior to mass spectral analysis”. Appellant respectfully submits that this is quite different from the instant invention since such harsh oxidation treatment will likely cause side reactions which could change the peptide structure and therefore give false results in mass spectrometry.

Appellant, thus, asserts that it is only with the teachings of the instant invention that a suitable methodology is obtained, and it is only with the use of the specific reagents recited within the methodology that such is attainable. Far from being a routine property, Appellants respectfully assert that the specific properties of the reagents in this invention are neither disclosed nor even suggested by the Keough, et al. reference.

In view of the foregoing, Appellant respectfully submits that the Examiner's rejection cannot be sustained and should be reversed.

**2. Claims 7–9 and 19 are not properly rejected under 35 U.S.C. § 103(a) as being unpatentable over Keough, et al (WO 00/43792) in view of Little, et al (USP 6,322,970).**

The Examiner has rejected claims 7–9 and 19 under 35 U.S.C. § 103(a) as "being unpatentable over Keough et al in view of Little et al (USP#6,322,970)".

Specifically, the Examiner stated, "the teachings of Keough et al are set forth above and differ from the instant claims by not disclosing a sulfonyl group being coupled to a particular ester such as N-hydroxysuccinimide (NHS) ester".

The Examiner continued, "Little et al discloses a process for determining the identity of a target polypeptide using mass spectroscopy (abstract). Little et al discloses that target polypeptides can be captured by conjugation to a solid support by immobilizing. The conjugation can be mediated through a linker such as a sulfo-N-hydroxysuccinimide (NHS) ester that facilitates conjugation of the polypeptide through its amino terminus..." The Examiner further stated, "claim 12 recites a step of protecting lysine residues prior to derivatizing. Little et al discloses that the termini of a target polypeptide are more reactive than the amino acid side groups and therefore the amino acid residues should be blocked prior to performing the reaction of interest (column 60, lines 27-50)".

The Examiner concluded, “it would have been obvious to one of ordinary skill in the art to modify the reference of Keough et al to couple an N-hydroxysuccinimide (NHS) ester to a sulfonyl group taught by Little et al to facilitate conjugation of peptides to a solid support which has the advantage of being manipulated so that reagents and undesirable reaction products can be washed from the remaining immobilized polypeptide, which can then be cleaved from the solid support and analyzed by mass spectrometry (column 60, lines 17-27)”.

In response, Appellant respectfully pointed out that the Little, et al. reference discloses the utilization of NHS esters to facilitate attachment to a solid support. As stated at column 4, lines 38–52, this immobilization provides “a means to isolate the polypeptide, as well as a means to manipulate the isolated target polypeptide prior to mass spectrometry”. Such is quite different from the instant invention wherein the derivatization is done in aqueous solution and does not require attachment to a solid support. The benefits of such aqueous solution derivatization are discussed above, and are neither disclosed nor even suggested by either the Keough, et al. or Little, et al. references.

In response to this argument, the Examiner has stated, “Applicant[’s] argument that the references of Keough et al and Little et al does not disclose or suggest derivatization of the peptides in aqueous solution. This argument is noted but not found to be persuasive”.

The Examiner continued, “In response to applicant’s arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Keough et al teaches derivatization in an aqueous solution, which are called for by the instant claim 1 (see page 5, lines 11-12). The reference of Little et al was relied on for its teaching of a particular (NHS) ester group, which discloses that (NHS) esters facilitate conjugation of the polypeptide to a solid support during the method of derivatization of the polypeptide through its amino or carboxyl terminus. Although applicant contends that the instant invention is different from the prior art of Keough et al and Little et al, these differences do not appear in the claims. Therefore, it appears to the examiner that the combination of the references is proper”.

In response, Appellant reiterated that the references, alone or in combination with one another, neither disclose nor even suggest derivatizing polypeptides in aqueous solution, nor do they disclose or even suggest that the reagents for derivatization exhibit a half-life in aqueous solution of not less than 10 minutes at room temperature. This is clearly recited in claim 1 (upon which claims 7–9 are dependent) and claim 15 (upon which claim 19 is dependent). Thus, Appellant respectfully asserts the differences between the instant invention and the prior art of Keough, et al. and Little, et al. do appear in the claims.

In response to this argument, the Examiner states, “Applicant argues that the reference of Keough and Little et al alone or in combination with one another neither discloses nor even suggest derivatizing polypeptides in aqueous solution, nor do they disclose or even suggest that the reagents for derivatization exhibit a half-life in aqueous solution of not less than 10 minutes at room temperature. This argument is noted but not found to be persuasive”.


In response, Appellant respectfully reasserts the arguments as to the inappropriateness of the rejection under the Keough, et al. reference and respectfully submits that the addition of the Little, et al. reference does nothing to remedy these deficiencies. Specifically, neither of these references alone or in combination with one another, discloses nor even suggests the claimed methodology inasmuch as the reagents are not taught. It is only with the teachings of the instant invention as presented in the captioned application that such is attainable.

In view of the foregoing, Appellant respectfully submits that the Examiner’s rejection cannot be sustained and should be reversed.

## Conclusion

In view of the foregoing arguments, Appellant respectfully asserts that the Examiner's rejections cannot be sustained, and should be reversed.

Respectfully submitted,



Royal N. Ronning, Jr.  
Registration No.: 32,529  
Attorney for Appellant

Amersham Biosciences Corp  
800 Centennial Avenue  
P. O. Box 1327  
Piscataway, New Jersey 08855-1327

Tel: (732) 457-8423  
Fax: (732) 457-8463

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Appeal Brief – Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on October 26, 2005.

Signature: 

Name: Melissa Leck



## CLAIMS APPENDIX

### The Rejected Claims

Claim 1 (original): A method of identifying a polypeptide, which method comprises the steps of

- (a) derivatizing, in an aqueous solution, the N-terminus of the polypeptide, or the N-termini of one or more peptides of the polypeptide, with at least one acidic reagent containing a sulfonyl moiety coupled to an ester moiety to provide one or more peptide derivatives, which reagent exhibits a half-life in aqueous solution of not less than 10 minutes at room temperature, to prepare one or more derivatives;
- (b) analyzing at least one said derivative using a mass spectrometric technique to provide a fragmentation pattern; and
- (c) interpreting the fragmentation pattern obtained to identify the polypeptide.

Claim 2 (original): The method according to claim 1, wherein the acidic reagent has a pKa of less than about 2 when coupled to the polypeptide.

Claim 3 (original): The method according to claim 1, wherein the mass spectrometric technique used in step (b) is matrix-assisted laser desorption ionization (MALDI) mass spectrometry.

Claim 4 (original): The method according to claim 1, wherein the mass spectrometric technique used in step (b) is electrospray ionization (ESI).

Claim 5 (original): The method according to claim 1, wherein in step (c), the fragmentation pattern is interpreted using a software program or database.

Claim 6 (original): The method according to claim 1, wherein all the steps are conducted as part of an automated or semi-automated procedure.

Claim 7 (previously presented): The method according to claim 1, wherein the acidic reagent includes an N-hydroxysuccinimide (NHS) ester.

Claim 8 (original): The method according to claim 7, wherein the reagent comprises a 3-sulfopropionic acid N-hydroxysuccinimide ester.

Claim 9 (original): The method according to claim 7, wherein the reagent comprises a 2-sulfobenzoic acid N-hydroxysuccinimide ester.

Claim 10 (original): The method according to claim 1, wherein the polypeptide has been obtained by enzymatic digestion.

Claim 11 (original): The method according to claim 10, wherein the enzyme is trypsin.

Claim 12 (original): The method according to claim 1, which further comprises a step of protecting lysine residues prior to the derivatizing step.

Claims 13–14 (cancelled)

Claim 15 (original): A kit for identifying a polypeptide by a mass spectrometric technique, which kit comprises at least one acidic reagent comprising a sulfonyl moiety coupled to an activated acid moiety in a container, which reagent exhibits a half-life in aqueous solution of not less than 10 minutes, preferably not less than about 20 minutes and most preferably not less than about 30 minutes at RT.

Claim 16 (original): The kit according to claim 15, wherein the reagent has a pKa of less than about 2 when coupled to the polypeptide.

Claim 17 (original): The kit according to claim 15, wherein the mass spectrometric technique is matrix-assisted laser desorption ionization (MALDI) mass spectrometry.

Claim 18 (original): The kit according to claim 15, wherein the mass spectrometric technique is electrospray ionization (ESI).

Claim 19 (original): The kit according to claim 15, wherein the activated acid moiety is an N-hydroxysuccinimide (NHS) ester.

Claim 20 (original): A kit according to claim 19, wherein the NHS ester is selected from the group consisting of 3-sulfopropionic acid N-hydroxysuccinimide ester and 2-sulfobenzoic acid N-hydroxysuccinimide ester.



## EVIDENCE APPENDIX

Appellant hereby appends a copy of U.S. Patent 6,322,970 to Little, et al. and a copy of international patent application number PCT/US00/00790, which published as WO 00/43792. This is the evidence relied upon by the Examiner for rejection of appealed claims.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,322,970 B1  
DATED : November 27, 2001  
INVENTOR(S) : Little et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page.

Please add to Item [\*] Notice: -- This patent is subject to a terminal disclaimer. --  
Item [56], **References Cited**, replace patent number "4,681,394" with -- 4,683,194 --.  
Add the following:  
-- Sinha et al., Polymer support oligonucleotide synthesis XVIII: Use of beta-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of final products, Nucleic Acid Res. 12:4539 (1984). --

Column 77,

Lines 24 and 25, claim 28 should read as follows:  
-- 28. The process of claim 27, wherein the encoded polypeptide is isolated by reaction with an antibody. --

Signed and Sealed this

Second Day of July, 2002

*Attest:*



*Attesting Officer*

JAMES E. ROGAN  
*Director of the United States Patent and Trademark Office*



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :  G01N 33/68		A2	(11) International Publication Number: <b>WO 00/43792</b>  (43) International Publication Date: 27 July 2000 (27.07.00)
<p>(21) International Application Number: PCT/US00/00790</p> <p>(22) International Filing Date: 12 January 2000 (12.01.00)</p> <p>(30) Priority Data: 60/116,502 20 January 1999 (20.01.99) US 60/156,677 29 September 1999 (29.09.99) US</p> <p>(71) Applicant (for all designated States except US): THE PROCTER &amp; GAMBLE COMPANY [US/US]; One Procter &amp; Gamble Plaza, Cincinnati, OH 45202 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): KEOUGH, Thomas, Woods [US/US]; 9896 Barnsley Court, Cincinnati, OH 45242 (US). YOUNGQUIST, Robert, Scott [US/US]; 8511 Charleston Knoll Court, Mason, OH 45040 (US).</p> <p>(74) Agents: REED, T., David et al.; The Procter &amp; Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: METHODS AND KITS FOR SEQUENCING POLYPEPTIDES</p> <p>(57) Abstract</p> <p>The present disclosure provides methods and kits which are useful for sequencing polypeptides. The methods involve derivatization of the N-terminus of the polypeptide or peptides thereof. Mass spectral analysis of one or more of the resulting derivatized analytes provides spectra which are readily interpreted through the use of techniques well-known to the ordinarily skilled artisan. The present disclosure also describes kits which enhance convenient performance of the methods.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## METHODS AND KITS FOR SEQUENCING POLYPEPTIDES

5

## FIELD OF THE INVENTION

The present invention relates to methods and kits which enable polypeptide sequencing using mass spectrometric techniques. The methods and kits are particularly useful for identifying high molecular weight polypeptides for use in, for example, biological, pharmaceutical, personal cleansing, and fabric cleaning fields.

10

## BACKGROUND OF THE INVENTION

Recently, matrix-assisted laser desorption ionization (MALDI) mass spectrometry and electrospray ionization were developed for high-sensitivity peptide and polypeptide sequencing applications. See, e.g., Spengler et al., "Peptide Sequencing by Matrix-assisted Laser-desorption Mass Spectrometry", *Rapid Communications in Mass Spectrometry*, Vol. 6, pp. 105 - 108 (1992); Spengler et al., "Fundamental Aspects of Postsource Decay in Matrix-Assisted Laser Desorption Mass Spectrometry", *Journal of Physical Chemistry*, Vol. 96, pp. 9678 - 9684 (1992); Kaufmann et al., "Mass Spectrometric Sequencing of Linear Peptides by Product-ion Analysis in a Reflectron Time-of-flight Mass Spectrometer Using Matrix-assisted Laser Desorption Ionization", *Rapid Communications in Mass Spectrometry*, Vol. 7, pp. 902 - 910 (1993); Kaufmann et al., "Sequencing of Peptides in a Time-of-flight Mass Spectrometer: Evaluation of Postsource Decay Following Matrix-assisted Laser Desorption Ionisation (MALDI)", *International Journal of Mass Spectrometry and Ion Processes*, Vol. 131, pp. 355 - 385 (1994); Kaufmann et al., "Post-source Decay and Delayed Extraction in Matrix-assisted Laser Desorption/Ionization-Reflectron Time-of-Flight Mass Spectrometry", *Rapid Communications in Mass Spectrometry*, Vol. 10, pp. 1199 - 1208 (1996); and Spengler, "Post-source Decay Analysis in Matrix-assisted Laser Desorption/Ionization Mass Spectrometry of Biomolecules", *Journal of Mass Spectrometry*, Vol. 32, pp. 1019 - 1036 (1997); Carr et al., "Integration of Mass Spectrometry in Analytical Biotechnology", *Analytical Chemistry*, Vol. 63, pp. 2802 - 2824, (1991); Yates III et al., "Mining Genomes With MS", *Analytical Chemistry*, Vol. 68, pp. 534A - 540A, (1996); Morris et al., "High Sensitivity Collisionally Activated Decomposition Tandem Mass Spectrometry on a Novel Quadrupole/Orthogonal Acceleration Time-of-Flight Mass Spectrometer", *Rapid Communications in Mass Spectrometry*, Vol. 10, 889 - 896, (1996).

5 MALDI offers several advantages in the field of mass spectrometry. For example, MALDI provides higher sensitivity than conventional electrospray triple quadrupole equipment. When used in combination with time-of-flight mass analyzers, MALDI is also applicable to higher mass peptides than can be analyzed with triple quadrupole equipment. MALDI is also useful for analyzing complex mixtures with minimal sample purification. Electrospray ionization, on the other hand, is readily interfaced to powerful separation techniques including liquid chromatography (LC) and various forms of capillary electrophoresis (CE). Highly automated analyses are possible when using LC and CE as the sample purification and introduction devices.

10 However, current MALDI and, to a lesser extent, electrospray ionization mass spectrometric methods fail to adequately offer predictable tandem mass spectrometry fragmentation patterns. For example, multiple ion series (including a-ions, b-ions, and y-ions) are typically observed, resulting in MALDI post-source decay spectra that are too complex for efficient interpretation and sequencing. Multiple ion series (b- and y-ions), plus internal fragments and both singly and multiply charged ions are formed from multiply charged precursor ions generated by electrospray ionization, and the resulting tandem mass spectra are often difficult to interpret de novo. Accordingly, problems with fragmentation have limited the ability 15 to rapidly sequence polypeptides using mass spectrometry. As a result, mass spectrometry, and particularly MALDI mass spectrometry, is of limited value in this area.

20 Several research groups have attempted to improve the utility of mass spectrometry in the field of polypeptide sequencing through the use of chemical derivatization techniques. Such techniques have been utilized to promote and direct fragmentation in the MSMS spectra of peptides with the goal of increasing sensitivity and decreasing the complexity of the resulting spectra. Most of these known techniques provide cationic derivatives. See, e.g., Kidwell et al., 25 "Sequencing of Peptides by Secondary Ion Mass Spectrometry", Journal of the American Chemical Society, Vol. 106, pp. 2219 - 2220 (1984) (derivatization with a quaternary ammonium group, analysis using the static SIMS ionization method (prior to development of both MALDI and electrospray ionization)). Application of such techniques using MALDI and electrospray ionization with low-energy collisional activation have not proven generally effective.

30 More recently, researchers have utilized other derivatization techniques in an effort to enhance peptide / polypeptide sequencing using mass spectrometric methods. For example, it has been shown that oxidation of cysteine residues present in tryptic peptides (peptides produced via digestion with trypsin) may improve fragmentation using electrospray tandem mass spectrometry. See, e.g., Gaskell et al., "Role of the Site of Protonation in the Low-Energy Decompositions of 35 Gas-Phase Peptide Ions", Journal of the American Society of Mass Spectrometry, Vol. 7, pp. 522 - 531 (1996) and Gaskell et al., "Influence of Cysteine to Cysteic Acid Oxidation on the

Collision-Activated Decomposition of Protonated Peptides: Evidence for Intraionic Interactions", Journal of the American Society of Mass Spectrometry, Vol. 3, pp. 337 - 344 (1992).

Specifically, y-ion fragmentation was promoted. However, this technique has several limitations. For example, the technique was not extended to MALDI methods. The technique is also limited to the analysis of those polypeptides having cysteine residues occurring in the sequence to be analyzed. Indeed, cysteine occurs rather rarely in naturally occurring polypeptides, placing a severe limitation on the utility of this technique.

Accordingly, there is a need to provide a mass spectrometric method of sequencing polypeptides that is simple, efficient, and widely applicable to wild-type and variant polypeptides.

The present inventors herein provide a method for high-sensitivity polypeptide sequencing using mass spectrometric techniques. The present inventors have discovered that polypeptides and peptides thereof derivatized with relatively strong acid groups will provide y-ion fragmentation nearly exclusively, resulting in spectra which are easily interpreted de novo. The present invention is also related to kits which are used to conveniently enable performance of the present method.

#### SUMMARY OF THE INVENTION

The present invention relates to mass spectrometric methods and kits which are particularly useful for sequencing polypeptides. The methods involve determining the amino acid sequence of a polypeptide, the steps comprising:

- 20 (a) derivatizing the N-terminus of the polypeptide or the N-termini of one or more peptides of the polypeptide with one or more acidic moieties having a pKas of less than about 2 when coupled with the polypeptide or peptides, to provide one or more derivatized analytes;
- 25 (b) analyzing one or more derivatized analytes using a mass spectrometric technique to provide a fragmentation pattern; and
- (c) interpreting the fragmentation pattern.

The kits of the present invention comprise one or more acidic moiety reagents which provide acidic moieties having pKas of less than about 2 when coupled with a polypeptide; and means for derivatizing the N-terminus of the polypeptide or the N-termini of one or more peptides of the polypeptide with one or more acidic moiety reagents. The present kits are particularly useful in conjunction with performance of the methods.

#### DETAILED DESCRIPTION OF THE INVENTION

The methods and kits of the present invention are useful for sequencing polypeptides including, for example, wild-type, variant, and / or synthetic polypeptides. The methods and kits

are particularly useful for identifying high molecular weight polypeptides for use in, for example, biological, pharmaceutical, personal cleansing, and fabric cleaning fields.

The present methods and kits have widespread utility. Applications include, but are not limited to: facilitation of biological studies requiring rapid determination of peptide or polypeptide sequences; identification of post-translational modifications in proteins and for the identification of amino acid modifications in variant proteins such as those used in, for example, commercial laundry and cleansing products; aiding the design of oligonucleotide probes for gene cloning; rapid characterization of products formed in directed evolution studies; combinatorial chemistry and peptide library identification; and proteomics.

The present method involves addition of one or more relatively strong acid groups to the N-terminus of the polypeptide or one or more peptides formed through cleavage of the polypeptide prior to mass spectrometric analysis. Without intending to be limited by theory, it is believed that the resulting negatively charged derivative(s) facilitate low energy charge-site initiated fragmentation. This is especially effective wherein the C-termini of the polypeptide or peptides thereof are basic or hydrophobic, preferably basic residues. Again, without limitation by theory, it is believed that wherein a basic residue is protonated during mass spectrometric analysis, the relatively strong acid group will be deprotonated, which counter-balances the positive charge at the basic residue. An additional proton to ionize the derivative will be substantially "free" to randomly ionize the backbone amide groups of the polypeptide / peptide because the most basic residue is already protonated. Additionally, without limitation by theory, it is believed that wherein a second relatively strong acid group is incorporated into the polypeptide / peptide that both acid groups will be deprotonated, providing two substantially "free" protons to randomly ionize the backbone amide groups of the polypeptide / peptide.

Utilization of the present method provides significant increases in fragmentation efficiencies. Furthermore, increased fragment ion signal-to-noise ratios are observed for derivatized peptides relative to non-derivatized peptides having the same sequences. The resulting simple PSD MALDI and electrospray tandem mass spectra can be routinely interpreted *de novo*.

Publications and patents are referred to throughout this disclosure. All references cited herein are hereby incorporated by reference.

All percentages, ratios, and proportions used herein are by weight unless otherwise specified.

As used herein, abbreviations will be used to describe amino acids. Such abbreviations are described in Table I below. Further described in Table I are average amino acid residue masses which are useful for the practice of the present invention.

Table I

Amino Acid	Three-letter Abbreviation	One-Letter Abbreviation	Average Amino Acid Residue Mass (Da)
Alanine	Ala	A	71.1
Arginine	Arg	R	156.2
Asparagine	Asn	N	114.1
Aspartic Acid	Asp	D	115.1
Cysteine	Cys	C	103.1
Glutamine	Gln	Q	128.1
Glutamic Acid	Glu	E	129.1
Glycine	Gly	G	57.1
Histidine	His	H	137.1
Isoleucine	Ile	I	113.2
Leucine	Leu	L	113.2
Lysine	Lys	K	128.2
Methionine	Met	M	131.2
Phenylalanine	Phe	F	147.2
Proline	Pro	P	97.1
Serine	Ser	S	87.1
Threonine	Thr	T	101.1
Tryptophan	Trp	W	186.2
Tyrosine	Tyr	Y	163.2
Valine	Val	V	99.1

#### Definitions

As used herein, the term "desorption ionization" refers to the transition of an analyte from the solid-phase to the gas-phase as ions.

As used herein, the term "desorption" refers to the departure of analyte from the surface and / or the entry of the analyte into a gaseous phase.

As used herein, "ionization" refers to the process of creating or retaining on an analyte an electrical charge equal to plus or minus one or more electron units.

As used herein, the term "MALDI" refers to matrix-assisted laser desorption ionization.

As used herein, the term "matrix" in reference to "MALDI" refers to small, acidic, light absorbing chemicals which may be mixed in solution with the polypeptide of interest, or peptides

thereof, of interest in such a manner so that, upon drying on the sample stage, the crystalline matrix-embedded analytes can be successfully desorbed and ionized from the solid-phase into the gaseous or vapor-phase following laser irradiation. Alternatively, solutions of polypeptides, or peptides thereof, may be loaded onto appropriate matrices which are pre-dried on the sample stage. Non-limiting examples of suitable matrices include nicotinic acid, sinapinic acid, ferulic acid, caffeic acid, a-cyano-4-hydroxycinnamic acid, and a-cyano-4-hydroxycinnamic acid mixed with nitrocellulose.

As used herein, the term "electrospray ionization" refers to the process of producing ions from solution by electrostatically spraying the solution from a capillary electrode at high voltage with respect to a grounded counter electrode. The definition is intended to include both electrospray ionization and pneumatically assisted electrospray ionization, which is also referred to as ionspray. As used herein, the term "electrospray ionization" applies to all liquid flow rates and is intended to include microspray and nanospray experiments. Moreover, the definition is intended to apply to the analyses of peptides directly infused into the ion source without separation, and to the analysis of peptides or peptide mixtures that are separated prior to electrospray ionization. Suitable on-line separation methods include, but are not limited to, HPLC, capillary HPLC and capillary electrophoresis. Electrospray ionization experiments can be carried out with a variety of mass analyzers, including but not limited to, triple quadrupoles, ion traps, orthogonal-acceleration time-of-flight analyzers and Fourier Transform Ion Cyclotron Resonance instruments.

As used herein, the term "polypeptide" refers to a molecule having two or more amino acid residues. The method of the present invention is suitable for sequence identification of high mass polypeptides.

As used herein, the term "wild-type" refers to a polypeptide produced by unmutated organisms.

As used herein, the term "variant" refers to a polypeptide having an amino acid sequence which differs from that of the wild-type polypeptide.

#### Methods of the Present Invention

The present method is useful for determining the amino acid sequence of a polypeptide. By using the phrase "determining the amino acid sequence", the present inventors do not intend to be limited to determining the entire sequence of a given polypeptide. Rather, by this phrase it is meant herein that a portion, portions, and / or the entire sequence is determined.

The present methods involve addition of one or more relatively strong acid groups to the N-terminus of a polypeptide or one or more peptides thereof to produce one or more derivatized analytes for mass spectrometric analysis. The polypeptide / peptides are then analyzed using a

mass spectrometric technique to provide a fragmentation pattern. The resulting fragmentation pattern is interpreted, thereby allowing sequencing of the polypeptide.

The present inventors have discovered that the acidity of the derivatizing group(s) (acidic moiety) has a profound effect on the resulting mass spectra. Surprisingly, those acidic moieties having a pKa of less than about 2 when coupled with a polypeptide or peptide thereof will yield fragmentation patterns which are easily interpreted to provide the desired sequence information. The ordinarily skilled artisan is competent to measure the pKa values as described herein using standard methods known in the art. Non-limiting examples of such methods include, for example, titration and electrochemical methods. The preferred method of measuring pKa values is through titration.

The method of the present invention may be performed as follows:

#### Derivatization of Polypeptide and / or Peptides of the Polypeptide

An important feature of the present invention is derivatization of a polypeptide or peptides of a polypeptide of interest with one or more a relatively strong acids, i.e., acidic moieties having pKas less than about 2, preferably less than about 0, and more preferably less than about -2, when coupled with a polypeptide or peptides of the polypeptide. By "peptides of a polypeptide" it is meant herein that the polypeptide is digested or otherwise cleaved (herein collectively referred to as "digestion" or the like) into two or more peptides. The resulting peptides are derivatized in accordance with the present method. By "when coupled" it is meant herein that the pKas of the acidic moieties is defined as measured after being covalently bonded with a polypeptide or peptide herein.

The polypeptide or peptides thereof may be produced by any means. For example, if necessary, the polypeptide of interest is isolated for analysis. Several procedures may be utilized for isolation including, for example, one-dimensional and two-dimensional gel electrophoresis. As another example, polypeptides may be synthesized through combinatorial chemistry methods well known in the art.

Digestion may occur through any number of methods, including in-gel or on a membrane, preferably in-gel. See, e.g., Shevchenko et al., "Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels", *Analytical Chemistry*, Vol. 68, pp. 850 - 858 (1996). However, it is possible to digest the polypeptide either enzymatically or chemically, preferably enzymatically. It is most preferable to utilize a digestion procedure which yields a basic or hydrophobic residue, most preferably basic, at or near the C-terminus of the resulting peptides. By "at" it is meant herein that the basic or hydrophobic residue is the C-terminal residue of the peptide. By "near" it is meant herein that the basic or hydrophobic residue is preferably within about 40 amino acid residues from the C-terminus of the peptide, more preferably within about 30

residues, even more preferably about 20 residues, and most preferably within 10 amino acid residues from the C-terminus of the peptide.

While many methods may be utilized for this procedure, it is preferred to enzymatically digest the polypeptide using, for example, trypsin, endoproteinase Lys C, endoproteinase Arg C, or chymotrypsin, preferably, trypsin, endoproteinase Lys C, or endoproteinase Arg C, and most preferably trypsin. Trypsin, endoproteinase Lys C, and endoproteinase Arg C are preferable because the resulting peptides of the polypeptide will typically terminate at the C-terminus with an arginine or lysine residue (basic residues), with the exception, of course, of the original C-terminus of the polypeptide. Other enzymes are also suitable, especially if basic residues occur at or near the C-terminus of the resulting peptides. Chymotrypsin is also preferred for digestion, which typically cleaves at hydrophobic amino acid residues. Chemical digestion is also useful. For example, digestion with cyanogen bromide is useful.

10 The method of the present invention may be adapted according to that described in Patterson et al., U.S. Patent No. 5,821,063, assigned to PerSeptive Biosystems, Inc., issued October 13, 1998, particularly with respect to the digestion techniques described therein. For example, a plurality of samples having different ratios of agent to polypeptide may be utilized and derivatized according to the present invention.

15 However, digestion is not always necessary, particularly when sequencing (but certainly not limited to) small polypeptides. As used herein, "small" polypeptides include those having preferably less than about fifty amino acid residues, more preferably less than about forty residues, even more preferably less than about thirty residues, still more preferably less than about twenty residues, and most preferably less than about ten amino acid residues.

20 For example, polypeptides may be characterized which are synthesized by well-known means, including combinatorial chemistry methods (a "synthetic polypeptide"). In this instance, it is most preferable to synthesize a polypeptide having basic or hydrophobic residue, preferably basic (most preferably arginine or lysine), at or near the C-terminus of the resulting polypeptide.

25 The polypeptide (if the polypeptide is sufficiently "small" as defined herein above) or the peptides of the polypeptide are derivatized with one or more acidic moieties having pKas of less than about 2, preferably less than about 0, and most preferably less than about -2 (when coupled with the polypeptide or peptides) to provide a derivatized analyte. The acidic moieties of the derivatized analyte are prepared by coupling with an acidic moiety reagent. The acidic moiety reagent is not limited, provided an acidic moiety on the polypeptide or peptides thereof results having the herein described pKa. Non-limiting examples of acidic moiety reagents which may be utilized for coupling include, for example, dithiobis(sulfosuccinimidylpropionate), S-acetylmercaptopsuccinic anhydride, 2-iminothiolane (which may also be referred to as Traut's

reagent), dithiodiglycolic anhydride, tetrafluorosuccinic anhydride, hexafluoroglutaric anhydride, sulfosuccinic anhydride, 2-sulfobenzoic acid cyclic anhydride, chlorosulfonylacetyl chloride, and 1,3-propane sultone. Use of reagents such as S-acetylmercaptosuccinic anhydride, 2-iminothiolane, and dithiodiglycolic anhydride require oxidation after derivatization with the peptide to produce the acidic moiety. Acidic moiety reagents not requiring the oxidation step include, for example, tetrafluorosuccinic anhydride, hexafluoroglutaric anhydride, sulfosuccinic anhydride, 2-sulfobenzoic acid cyclic anhydride and chlorosulfonylacetyl chloride. These reagents are often preferred, due to more efficient synthesis and / or lack of complicating oxidation of labile residues in the polypeptide or peptides thereof. Coupling an acidic moiety reagent to the N-terminus of a cysteine-containing peptide, followed by oxidation of the cysteine sulphydryl group to cysteic acid, is one means to produce peptides containing two acidic moieties (sulfonic acids).


The acidic moieties are most preferably a sulfonic acid. Among these, the more preferred acidic moieties include 2-sulfoacetyl moiety, 3-sulfopropionyl moiety, and 2-sulfobenzoyl moiety.

The use of disulfonic acid derivatives is also preferred. Use of the disulfonic acid derivatives preferably results in both sulfonic acids groups near the N-terminus of the peptide. For example, coupling an acidic moiety reagent to the N-terminus of a cysteine-containing peptide, followed by oxidation of the cysteine sulphydryl group to cysteic acid is one means to produce peptides containing two acidic moieties (sulfonic acids).

The ordinarily skilled artisan will have the ability to perform the relatively simple coupling procedures required by the present invention. For convenience, however, non-limiting examples of derivatization of polypeptides, or peptides of the polypeptide of interest, are illustrated as follows:

25


## Example 1



2-Sulfobenzoic acid cyclic anhydride (commercially available from Aldrich Chemical Co., Milwaukee, WI) is prepared at a concentration of 0.1 M in dry tetrahydrofuran prior to use. The polypeptide ASHLGLAR (1 nmol, commercially available from Sigma Chemical Co., St. Louis MO) (SEQ ID NO: 1) is diluted into 20  $\mu$ L of 0.05 M trimethylamine. The 2-sulfobenzoic acid cyclic anhydride solution (2  $\mu$ L) is added and the reaction mixture is vortexed for 30

seconds. The reaction proceeds for approximately 2 minutes at room temperature prior to dilution of the resulting derivatized analyte and mass spectral analysis. The concentration of the acidic moiety reagent is decreased by a factor of as much as 100 when derivatizing smaller quantities.

Example 2




5

ASHLGLAR (1 nmol, commercially available from Sigma Chemical Co., St. Louis MO) (SEQ ID NO: 1) is mixed with 2  $\mu$ L of 0.02 M sulfoacetic acid, which is formed by mixing 2  $\mu$ L of neat chlorosulfonyl acetyl chloride (commercially available from Aldrich Chemical Co., Milwaukee, WI) with 500  $\mu$ L of water. The mixture is dried and then reconstituted in 20  $\mu$ L of tetrahydrofuran:diisopropylethyl amine (4:1 v:v). 0.1 M chlorosulfonyl acetyl chloride (2  $\mu$ L, commercially available from Aldrich Chemical Co., Milwaukee, WI) in dry tetrahydrofuran is added and the mixture is vortexed for 30 seconds. The derivatization reaction proceeds for approximately two minutes at ambient temperature. The derivatized analyte is dried, reconstituted in 20  $\mu$ L water and further diluted prior to mass spectral analysis.

10 Chlorosulfonyl acetyl chloride is also a useful reagent for derivatization of 2D gel isolates, but a modified synthetic procedure provides more consistent product yields. The modified procedure is

15 discussed in Example 14.

Example 3




20

S-acetylmercaptopsuccinic anhydride (commercially available from Aldrich Chemical Co., Milwaukee, WI) is prepared at a concentration of 0.1 M in dry tetrahydrofuran prior to use. ASHLGLAR (1 nmol, commercially available from Sigma Chemical Co., St. Louis MO) (SEQ ID NO: 1) is diluted into 20  $\mu$ L of 0.05 M trimethylamine. The S-acetylmercaptopsuccinic anhydride solution (5  $\mu$ L) is added and the reaction mixture is vortexed for 30 seconds. The reaction proceeds for about two minutes at room temperature and is then oxidized with 10  $\mu$ L of formic acid (88%):H2O2 (30%) prepared at a ratio of 19:1 (v:v). Oxidation proceeds for 16 hours at room temperature, and the sample is dried prior to dilution and mass spectral analysis.

25


The concentration of the acidic moiety reagent is decreased by a factor of as much as 100 when derivatizing smaller quantities.

## Example 4



To ASHLGLAR (1 nmol, commercially available from Sigma Chemical Co., St. Louis, MO) (SEQ ID NO: 1) in 0.1 M trimethylamine (20  $\mu$ L) is added 2-iminothiolane (Traut's reagent, 5 commercially available from Aldrich Chemical Co., Milwaukee, WI) (3  $\mu$ L, 0.1 M in deionized water). The reaction proceeds for 5 minutes at room temperature. The product is oxidized with 3  $\mu$ L of formic acid (88%):H<sub>2</sub>O<sub>2</sub> (30%) prepared at a ratio of 19:1 (v:v). Oxidation proceeds for 5 minutes at room temperature, and the derivatized analyte is dried prior to mass spectral analysis.


## Example 5



10

The polypeptide CDPGYIGSR (commercially available from Sigma Chemical Co., St. Louis, MO) (SEQ ID NO: 2) is oxidized by mixing 1 to 5 nM of polypeptide (in 5 - 20  $\mu$ L water) with 10  $\mu$ L of formic acid (88%):H<sub>2</sub>O<sub>2</sub> (30%) prepared at a ratio of 19:1 (v:v). Oxidation proceeds for 30 minutes at room temperature, and the derivatized analyte is dried prior to mass 15 spectral analysis.


## Example 6



Dithiobis(sulfosuccinimidylpropionate) (DTSSP) (commercially available from Pierce Chemical Co., Rockford, IL) is taken up in phosphate-buffered saline at 50 nM / 20  $\mu$ L and the 20 pH is adjusted to 7.7 with 1 N NaOH. The solution (20  $\mu$ L) is added to 1  $\mu$ L of peptide HLGLAR

(at 1 nM /  $\mu$ L) (SEQ ID NO: 3) and allowed to react for 30 minutes. The reaction is quenched with tris-hydroxymethyl-aminomethane (0.1M, 20  $\mu$ L). The sample is desalted and oxidized with 10  $\mu$ L of formic acid (88%):H<sub>2</sub>O<sub>2</sub> (30%) prepared at a ratio of 19:1 (v:v). Oxidation proceeds for 30 minutes at room temperature, and the derivatized analyte is dried prior to mass spectral analysis.


5 Example 7



Dithiodiglycolic acid (0.93 g, 5.1 mmol, commercially available from Sigma Chemical Co., St. Louis, MO) (alternatively, a polymer thereof of anhydride thereof (cyclic or acyclic) may 10 be used) is dissolved in dichloromethane (20 mL) and placed under inert atmosphere. Dicyclohexylcarbodiimide (1.05 g, 5.1 mmol) is added in one portion. After about 96 hours, the precipitate is removed by filtration and the filtrate is concentrated in vacuo. The resulting material is taken up in diethylether and filtered. Again, the filtrate is concentrated in vacuo to provide dithiodiglycolic anhydride.

15 Dithiodiglycolic anhydride (the cyclic form is shown in this example) is prepared at a concentration of 0.1 M in dry tetrahydrofuran prior to use. ASHLGLAR (1 nmol) (SEQ ID NO: 1) is diluted into 20  $\mu$ L of 0.05 M trimethylamine. The dithiodiglycolic anhydride solution (5  $\mu$ L) is added and the reaction mixture is vortexed for 30 seconds. The reaction proceeds for about two minutes at room temperature. The resulting product is oxidized with 2  $\mu$ L of formic acid 20 (88%):H<sub>2</sub>O<sub>2</sub> (30%) prepared at a ratio of 19:1 (v:v). Oxidation proceeds for 30 minutes at room temperature, and the derivatized analyte is dried prior to mass spectral analysis. The concentration of the acidic moiety reagent is decreased by a factor of as much as 100 when derivatizing smaller quantities.


## Example 8



3-Sulfopropionic anhydride is prepared at a concentration of 0.1 M in dry tetrahydrofuran prior to use. ASHLGLAR (1 nmol) (SEQ ID NO: 1) is diluted into 20  $\mu$ L of tetrahydrofuran:diisopropylethylamine 4:1 (v:v). The 3-sulfopropionic anhydride solution (2  $\mu$ L) is added and the reaction mixture is vortexed for 30 seconds. The reaction proceeds for about two minutes at room temperature prior to dilution and mass spectral analyses. The concentration of the acidic moiety reagent is decreased by a factor of as much as 100 when derivatizing smaller quantities.

10


## Example 9



15

Tetrafluorosuccinic anhydride is prepared at a concentration of 0.1 M in dry tetrahydrofuran prior to use. ASHLGLAR (1 nmol) (SEQ ID NO: 1) is diluted into 20  $\mu$ L of 0.05 M trimethylamine. The tetrafluorosuccinic anhydride solution (2  $\mu$ L) is added and the reaction mixture is vortexed for 30 seconds. The reaction proceeds approximately two minutes at room temperature prior to dilution and mass spectral analysis. The concentration of the coupling reagent is decreased by a factor of approximately 100 when derivatizing smaller quantities.

## Example 10



20

The polypeptide CDPGYIGSR (commercially available from Sigma Chemical Company, St. Louis, MO)(SEQ ID NO: 2) is mixed with 2  $\mu$ L of 0.02M sulfoacetic acid, which is formed by mixing 2  $\mu$ L of neat chlorosulfonyl acetyl chloride (commercially available from Aldrich

Chemical Co., Milwaukee, WI) with 500  $\mu$ L of water. The mixture is dried and reconstituted in 20  $\mu$ L of tetrahydrofuran:diisopropylethyl amine (4:1 v/v). 0.1 M chlorosulfonylacetyl chloride (2  $\mu$ L) in dry tetrahydrofuran is added and the mixture is vortexed for 30 sec. The derivatization reaction proceeds for about 2 min. at ambient temperature. The derivatized analyte is dried and 5 reconstituted in 10  $\mu$ L of water. To that solution is added 10  $\mu$ L of formic acid (88%):H<sub>2</sub>O<sub>2</sub>(30%) prepared at a ratio of 19:1 (v:v). Oxidation proceeds for 5 min. at room temperature, producing the derivatized peptide having two sulfonic acid groups near the N-terminus.

Analysis Using a Mass Spectrometric Technique

Upon derivatization, the polypeptide or one or more peptides of the polypeptide are analyzed using a mass spectrometric technique. While the technique utilized is not limited, the preferred techniques are post-source decay (PSD) matrix-assisted laser desorption ionization (MALDI) and electrospray ionization tandem mass spectrometry. See, e.g., Spengler et al., "Peptide Sequencing by Matrix-assisted Laser-desorption Mass Spectrometry", *Rapid Communications in Mass Spectrometry*, Vol. 6, pp. 105 - 108 (1992); Spengler et al., "Fundamental Aspects of Postsource Decay in Matrix-Assisted Laser Desorption Mass Spectrometry", *Journal of Physical Chemistry*, Vol. 96, pp. 9678 - 9684 (1992); Kaufmann et al., "Mass Spectrometric Sequencing of Linear Peptides by Product-ion Analysis in a Reflectron Time-of-flight Mass Spectrometer Using Matrix-assisted Laser Desorption Ionization", *Rapid Communications in Mass Spectrometry*, Vol. 7, pp. 902 - 910 (1993); Kaufmann et al., "Sequencing of Peptides in a Time-of-flight Mass Spectrometer: Evaluation of Postsource Decay Following Matrix-assisted Laser Desorption Ionization (MALDI)", *International Journal of Mass Spectrometry and Ion Processes*, Vol. 131, pp. 355 - 385 (1994); Kaufmann et al., "Post-source Decay and Delayed Extraction in Matrix-assisted Laser Desorption/Ionization-Reflectron Time-of-Flight Mass Spectrometry", *Rapid Communications in Mass Spectrometry*, Vol. 10, pp. 1199 - 1208 (1996); and Spengler, "Post-source Decay Analysis in Matrix-assisted Laser Desorption/Ionization Mass Spectrometry of Biomolecules", *Journal of Mass Spectrometry*, Vol. 32, pp. 1019 - 1036 (1997); Carr et al., "Integration of Mass Spectrometry in Analytical Biotechnology", *Analytical Chemistry*, Vol. 63, pp. 2802 - 2824, (1991); Yates III et al., "Mining 10 Genomes With MS", *Analytical Chemistry*, Vol. 68, pp. 534A - 540A, (1996); Morris et al., "High Sensitivity Collisionally Activated Decomposition Tandem Mass Spectrometry on a Novel Quadrupole/Orthogonal Acceleration Time-of-Flight Mass Spectrometer", *Rapid Communications in Mass Spectrometry*, Vol. 10, 889 - 896, (1996). Most preferably, the techniques utilized are positive ion mode PSD MALDI and electrospray ionization tandem mass

spectrometry. For convenience, Examples 11 and 12 below illustrate mass spectrometric techniques which may be utilized to analyze the polypeptide or peptides thereof.

As the present inventors have surprisingly discovered, appropriately derivatized peptides or peptides of the polypeptide provide MSMS spectra predominantly characterized by y-ions. As is well-known in the art, y-ions indicate ionized fragments containing the original C-terminus of the polypeptide or peptide. As used herein, the term "y-ion" also includes (y-NH<sub>3</sub>) ions; to illustrate, incomplete digestion products containing a second basic (for example) residue often yield abundant (y-NH<sub>3</sub>) ions. Preferably, the spectra produced by this method are substantially free of a-ions and b-ions. A-ions and b-ions are formed by cleavages on either side of backbone carbonyl groups. Importantly, charge is retained with the N-terminal fragment with a-ions and b-ions. As used herein, the term "substantially free of" with reference to a-ions and / or b-ions means that compared to the dominant y-ion series, a-ions and b-ions have a collective relative abundance of less than about 20%, preferably less than about 10%, and most preferably less than about 5%.

According to the method of the present invention, it is not necessary to analyze and / or identify all digestion products to identify the polypeptide thereof, particularly if the sequence of the polypeptide resides in a sequence database.

#### Example 11 - PSD MALDI Sequencing Technique

In this example, the mass spectrometric technique is carried out on a Voyager DE-RP or 20 Voyager DE-STR (PerSeptive Biosystems Inc., Framingham, MA) (or a suitable equivalent) equipped with a N2 laser (337 nm, 3 nsec pulse width, 20Hz repetition rate). The mass spectra are acquired in the reflectron mode with delayed extraction. External mass calibration is performed with a low-mass peptide standard, and mass measurement accuracy is typically  $\pm$  0.3 Da. The derivatized polypeptide or peptides are diluted to about 10 pM/ $\mu$ L in 0.1% 25 trifluoroacetic acid (TFA). The samples are then diluted five-fold to ten-fold further in a-cyano-4-hydroxycinnamic acid (alphaCN) which is prepared by dissolving 10 mg in 1 mL of aqueous 50% acetonitrile containing 0.1% TFA. See, e.g., Beavis et al., "a-Cyano-4-hydroxycinnamic Acid as a Matrix for Matrix-assisted Laser Desorption Mass Spectrometry", Organic Mass Spectrometry, Vol. 27, pp. 156 - 158 (1992). Gel isolates are analyzed from thin film surfaces of 30 a-cyano-4-hydroxycinnamic acid / nitrocellulose (alphaCN/NC) prepared by the fast evaporation method. See, e.g., Arnott et al., "An Integrated Approach to Proteome Analysis: Identification of Proteins Associated with Cardiac Hypertrophy", Analytical Biochemistry, Vol. 258, pp. 1 - 18 (1998).

PSD MALDI tandem mass spectra are acquired for the derivatized analyte after isolation 35 of the appropriate precursor ion using timed ion selection. The derivatized analytes can be

analyzed using a number of MALDI matrices including, but not limited to alphaCN, alphaCN/NC and 2,5-dihydroxybenzoic acid (DHB). Fragment ions are refocused onto the final detector by stepping the voltage applied to the reflectron. Typical voltage ratios which may be used are as follows: 1.0000 (precursor ion segment), 0.9126, 0.6049, 0.4125, 0.2738, 0.1975, and 0.1213 (fragment segments). The individual segments are combined (or "stitched together" as is commonly used in the art) using software commercially available from PerSeptive Biosystems, Framingham, MA ("PSD" is selected from the analysis window). All precursor ion segments are acquired at low laser power (variable attenuator = 1450) for < 256 laser pulses to avoid saturating the detector. The laser power is increased (variable attenuator = 1650) for all of the remaining segments of the PSD MALDI acquisitions. Typically, 256 laser pulses are acquired for each fragment ion segment. The data are acquired at a digitization rate of 20 MHz.

Example 12- An Electrospray Ionization Tandem Mass Spectrometry Sequencing Technique

In this example, the mass spectra are acquired using a capillary LC system (Perkin Elmer Biosystems, Foster City, CA) coupled to a LCQ ion trap mass spectrometer (ThermoQuest, San Jose, CA) equipped with a home-built microelectrospray source (uES). A 0.5 x 150 mm C18 LC column (Perkin Elmer Biosystems, Foster city, CA) is used with a flow rate of 5  $\mu$ l/min. The LC mobile phases are water and acetonitrile, each containing 0.02% TFA. A typical gradient is 15% acetonitrile for 5 min., then 15-60% acetonitrile over 40 min. Flow rates of 0.5  $\mu$ l/min to the uES source and 4.5  $\mu$ l/min to a UV detector are achieved by placing a splitting tee (1/16", 0.25 mm bore, Valco, Houston, TX) after the LC column. The derivatized peptide or polypeptide samples are injected onto the LC column with an autosampler (ALCOTT, model 719, Norcross, GA). The uES source is housed on an X,Y,Z micrometer (New Focus, Inc., Santa Clara, CA) mounted to the front end of the instrument. The microelectrospray needle is a PicoTip (FS360-50-15-D) from New Objective (Cambridge, MA).

The electrospray tandem mass spectra are acquired using the following instrumental conditions: spray needle voltage 1.5 kV, heated capillary temperature 200 °C, and collision energy 35 eV. A mass range of 300-2000 m/z is used in each full-MS scan. The electrospray tandem mass spectra are acquired using data-dependent scanning in the "triple-play" mode which consists of three sequential microscans: 1) a full MS scan, 2) a zoom on selected ions to determine charge states, and 3) a MS/MS scans on appropriate ions selected from the zoom scans. These three scan events are repeated throughout the LC run.

Interpreting the Fragmentation Pattern

The fragmentation pattern produced by the mass spectrometric analysis is interpreted to sequence the polypeptide. An artisan ordinarily skilled in the field of mass spectrometry will be

able to manually interpret the fragmentation patterns of small polypeptides *de novo* without the aid of commercially available software or sequence databases. Similarly, the artisan will also be capable of sequencing the peptides of the polypeptides (the digest products) *de novo*. Alternatively, the artisan may use known aids for interpretation including, for example, 5 commercially available software or sequence databases.

For example, sequences of the polypeptide or peptides thereof are efficiently and accurately determined with the y-ion fragmentation pattern produced via this invention. Identification of individual amino acid residues can be accomplished *de novo* by measuring mass differences between adjacent members in the y-ion series. Identification is then accomplished by 10 comparing the measured mass differences to the known amino acid residue masses (see Table I herein above). For example, a measured mass difference of 71.1 Da corresponds to alanine. The reading direction is also established directly from the mass spectrum. The direction is from the C-terminus to the N-terminus if measuring from low-mass to high-mass. The reading direction is from the N-terminus to the C-terminus if measuring from high-mass to low-mass.

15 The sequences of the polypeptide, and peptides thereof, may also be efficiently and accurately determined using software which accepts mass spectral fragmentation data, either uninterpreted y-ion series masses or sequence tags derived from the y-ion masses, as inputs for sequence database searches. Such search software commonly utilized by the skilled artisan include, but are not limited to, "Protein Prospector" (commercially available from the University 20 of California at San Francisco or <http://prospector.ucsf.edu>) and "Peptide Search" (commercially available from the European Molecular Biology Laboratory at Heidelberg, Germany or <http://www.mann.embl-heidelberg.de>).

The fragmentation pattern produced by this invention can be searched against a number 25 of sequence databases including, but not limited to, the NCBI non-redundant database (ncbi.nlm.nih.gov/blast/db.nr.z), SWISPROT (ncbi.nlm.gov/repository/SWISS-PROT/sprot33.dat.z), EMBL (FTP://ftp.ebi.ac.uk/pub/databases/peptidesearch/), OWL (ncbi.nlm.nih.gov/repository/owl/FASTA.z), dbEST (ncbi.nlm.nih.gov/repository/dbEST/dbEST.weekly.fasta.mmddyy.z) and Genebank (ncbi.nlm.nih.gov/genebank/genpept.fsa.z). The entire sequence of the polypeptide of interest 30 can often be retrieved from the sequence database by searching the fragmentation data produced from one or more of the relevant peptide derivatives formed using the methods of this invention.

Of course, when using database searching techniques, it is most efficient to limit the 35 searches by specifying that only y-ions or (y-NH<sub>3</sub>) ions are allowed fragments because y- and (y-NH<sub>3</sub>) ions are the most prominent species observed in the fragmentation patterns wherein the present methods are utilized. Other fragment ion types like a-, b-, (b+H<sub>2</sub>O), (b-H<sub>2</sub>O), (b-NH<sub>3</sub>)

and internal cleavage ions can be disallowed because they are not prominent in the spectra of the peptides derivatized using the methods of the present invention. The derivatives formed with the present invention provide simple fragmentation patterns that often yield greater database search specificity than can be obtained from the spectra of the same peptides without derivatization.

5 The methods of the present invention are further illustrated in the non-limiting examples below. In these examples, the ordinarily skilled artisan will recognize that numbers of "candidate proteins" produced may differ from those disclosed herein as new proteins are continually added to databases.

#### Example 13

10 PSD MALDI tandem mass spectrometry of high-mass polypeptides is demonstrated with oxidized insulin B-chain FVNQHLC(SO<sub>3</sub>H)GSHLVEALYLVC(SO<sub>3</sub>H)GERGFFYTPKA (SEQ ID NO: 4) (MMcalc = 3495.9 Da) (commercially available from Sigma Chemical Co., St. Louis, MO). The mass of this polypeptide far exceeds the upper limit of most conventional triple quadrupole instruments. The tandem mass spectrum of the native polypeptide shows a relatively intense ion series consisting substantially of y-ions. All y-ions between y9 and y24 are readily observed. The sequence-specific fragments defining the N-terminus of the molecule, y25 to y29, are absent from the spectrum.

15 The spectrum of this polypeptide is improved by derivatization using the acidic moiety reagent sulfobenzoic acid cyclic anhydride (commercially available from Aldrich Chemical Co., St. Louis, MO). The derivatized polypeptide shows significant enhancement of the y-ions derived from the N-terminal region of the molecule (y25, y26, y27, y28, and y29). A complete series of y-ions is observed from y8 to y29 following derivatization. No prominent b-ions are detected.

#### Example 14

20 A polypeptide separated by two-dimensional gel electrophoresis is in-gel digested with trypsin to produce peptides of the polypeptide. The peptides show several intense MH<sup>+</sup> signals by MALDI including ions at m/z 1060.8, 1090.8, 1271.0, 1299.0, 1312.0, 1344.0, 1399.1, 1450.1, 1460.1, and 1794.4. Database searching using the Protein Prospector Software against the entries in the NCBI protein sequence library produces a list of forty-one candidate proteins that match 25 five or more of the input tryptic masses (search parameters: MW range 1,000 to 150,000, isoelectric point from 3.0 to 10.0, oxidized Met allowed as a side-reaction and a conservative mass tolerance of +/- 0.6 Da).

30 The peptides of the polypeptide can be derivatized with any one of several of the reagents discussed in the previous examples. They include, but are not limited to, 2-sulfobenzoic acid cyclic anhydride, 3-sulfopropionic anhydride or chlorosulfonylacetil chloride. In this example,

chlorosulfonylacetyl chloride is used as the acidic moiety reagent. The derivatization procedure for low-level peptides isolated from 2D gel electrophoresis is modified to improve reproducibility and derivative yields. Typically, the peptide extract from the 2D gel is concentrated to near dryness (5 to 10  $\mu$ L) on a speed vac. The concentrates are acidified with 15  $\mu$ L of 0.1% TFA and 5 cleaned up using commercially available C18 mini-columns (ZipTip<sup>TM</sup>, Millipore Corporation, Bedford, MA 01730). The cleaned up sample is dried on a speed vac and reconstituted in 10  $\mu$ L of base (THF:DIEA 19:1 v/v). In this example, 2  $\mu$ L of a chlorosulfonylacetyl chloride solution (2  $\mu$ L of the neat liquid in 1 mL THF) is added and the reaction proceeds for 1 to 2 min at room temperature. The derivatized samples are again dried on a speed vac and reconstituted in 10  $\mu$ L 10 of 0.1% TFA prior to analysis. At this stage, the sample can be mixed with MALDI matrix and a portion loaded onto the sample stage for analysis, or it may be cleaned up again using a commercially available C18 mini-column (ZipTip<sup>TM</sup>, Millipore Corporation). The cleaned up sample can then be eluted directly from the ZipTip onto the MALDI sample stage in a 1 - 2  $\mu$ L 15 volume of acetonitrile:0.1% TFA (1:1 v/v) containing 10 mg/mL of MALDI matrix. This latter procedure allows loading all of the recovered derivatives onto the MALDI sample stage for analysis thereby improving overall sensitivity of the method. PSD MALDI tandem mass spectrometry is carried out on the derivatized peptide weighing about 1572 Da. A sequence tag is obtained having y-ions at m/z 574.5, 661.7, 875.9, 1003.8, 1103.9, 1204.6, 1304.1, and the (MH<sup>+</sup> - derivative) ion at m/z 1451.0. The spectrum is searched against the protein sequence database, 20 and six candidate proteins (all mitochondrial aspartate aminotransferases) are returned (search parameters: MW range 1,000 to 150,000, parent ion mass tolerance +/- 0.6 Da, fragment ion mass tolerance +/- 2.5 Da, Par(mi)Frag(av), allowed number of missed ions = 1). This level of specificity is obtained because the database search is constrained to consider y-ions as the only 25 allowed fragments. This search constraint is possible because N-terminal and internal cleavage ions are not prominent in the tandem mass spectra of these derivatives (due to derivatization according to the present invention). Much less specificity is obtained (239 candidate proteins returned) when this same tandem mass spectrum is searched against the full library and all fragment ion types (a, b, (b + H<sub>2</sub>O), (b - NH<sub>3</sub>), (b - H<sub>2</sub>O), internal and y) are allowed. The peptide was identified as FVTVQTISGTGALR (SEQ ID NO: 5).

30 Confirmation of the protein identification is sought by PSD MALDI of the derivative weighing about 1916 Da. The spectrum contains 7 fragment ions at m/z 724.6, 1154.2, 1299.3, 1439.0, 1551.9, 1665.5, and 1779.2, in addition to the protonated precursor ion. This spectrum is searched against the database assuming the fragments to be y-ions. The search does not return mitochondrial aspartate aminotransferase or any other candidate protein. Researching the

database allowing both y and (y - NH<sub>3</sub>) ions returns 16 candidate proteins, 10 of which are mitochondrial aspartate aminotransferases. This latter search confirms the protein identification. Inclusion of the (y - NH<sub>3</sub>) ions as possible fragments is required for this particular search because the peptide is an incomplete tryptic product (ILIRPLYSNPPLNGAR) (SEQ ID NO: 6) that contains a second arginine residue. As stated herein above, derivatized incomplete digestion products often exhibit (y - NH<sub>3</sub>) fragment ions in the PSD tandem mass spectra.

#### Example 15

An in-gel tryptic digest of a protein isolated from 2D gel electrophoresis is analyzed by LC electrospray tandem mass spectrometry on an LCQ ion trap following derivatization according to Example 14 herein. All spectra are acquired unattended in an automated data-dependent mode using the "triple play" sequence of microscans. The tandem mass spectrum of a derivatized tryptic peptide (MH<sup>+</sup> = 971.5) shows several y-type product ions including m/z 401.1, 538.3, 651.3, 750.4. The measured y-ions are used as inputs, along with the MH<sup>+</sup> mass of the underderivatized tryptic peptide (971.5 - 122 = 849.5), for database searching. Database searching using the Protein Prospector Software against the NCBI protein sequence library returns 3 candidate proteins (search parameters: MW range all, parent ion tolerance +/- 0.6 Da; fragment ion tolerance +/- 1.0 Da, monoisotopic parent and fragment ions, and no missed ions allowed). All three of the candidate proteins returned from the database search are haptoglobins. The peptide was identified as VVLHPER (SEQ ID NO: 7).

Confirmation of the protein identification is sought by searching the database using the tandem mass spectrum produced from a second derivatized peptide (MH<sup>+</sup> of derivative = 771.4 Da). The spectrum showed several ions including y-type ions at m/z 322.1, 436.2 and 535.3. Using the same search parameters as above, three peptide sequences match the input data from the electrospray tandem mass spectrum. One of the three peptide sequences corresponds to that of haptoglobin. The identification of that peptide was established as NVNFR (SEQ ID NO: 8). This result confirms the identity of the protein.

#### Example 16

The method of the present invention is readily utilized to identify variant polypeptides. The MALDI mass spectrum of a tryptic digest of an enzyme isolate shows many tryptic masses identical to those of the commercial protease Savinase® (commercially available from Novo Nordisk, Copenhagen, Denmark). One of the expected tryptic peptides GVLVVAASGNSGAGSISYPAR (MH<sup>+</sup> = 1933 Da) (SEQ ID NO: 9) is missing from the spectrum, and an unknown ion is observed at m/z 1963. This suggests that the isolate is a Savinase® variant. Eleven different single amino acid changes could account for the observed +30 Da mass shift (4 G → S, 4 A → T, and 3 V → E). The PSD MALDI tandem mass spectrum

is obtained following derivatization such as illustrated in Example 2 herein. A complete series of y-ions is observed for the 21 amino acid peptide. The spectrum verifies that the glycine at residue 14 is converted to a serine. The masses of all the y-ions are measured in this spectrum. The spectrum is automatically interpreted using the peptide ladder sequencing program, which is included in the PerSeptive Biosystems MALDI data system.

### Example 17

The use of disulfonic acid derivatives, with both sulfonic acid groups near the N-terminus of the peptide, is demonstrated by comparison of the MALDI PSD spectra produced from CDPGYIGSR (SEQ ID NO: 2) derivatized according to Example 5 and according to Example 10 herein. The derivative formed by performic acid oxidation of the sulphydryl group of the cysteine residue (Example 5) is analyzed using PSD MALDI from a matrix of alpha-cyano-4-hydroxycinnamic acid. The resulting PSD spectrum is dominated by the y7 fragment ion formed by cleavage of the labile Asp-Pro amide bond. Lower mass y-type ions show relatively low abundance. For example, the abundances of the y3 and y4 ions relative to the y7 ion are only about 8% and 5% respectively (peak height ratios). Without intending to be limited by theory, it is believed that the "mobile" ionizing proton is preferentially localized on the basic Asp-Pro amide nitrogen atom because the Pro amide nitrogen is more basic than the other backbone amide groups. This charge localization is thought to yield preferential fragmentation of the amide bond between Asp and protonated Pro. This problem is minimized by addition of a second sulfonic acid group near the N-terminus of the peptide according to Example 10. Addition of the second sulfonic acid group requires addition of a second "mobile" proton to produce the positively charged ion used for MALDI PSD analysis. Again, without intending to be limited by theory, this second proton is believed to be free to ionize other backbone amide groups because the relatively basic Pro group is already ionized. Protonation of other backbone amide groups leads to enhanced fragmentation of those groups and increased relative abundance of the corresponding y-ions in the MALDI PSD spectrum. In the PSD spectrum of the derivative formed according to Example 10, the abundances of the y3 and y4 ions increase to about 41% and 57% respectively (peak height ratios) relative to that of the y7 ion.

## Kits of the Present Invention

30 A further embodiment of the present invention are kits which may be utilized to determine the amino acid sequence of a polypeptide. The kits comprise:

(a) one or more acidic moiety reagents providing acidic moieties having  $pK_a$ s less than about 2 when coupled with the polypeptide or one or more peptides of the polypeptide; and

(b) means for derivatizing the N-terminus of the polypeptide or the N-termini of one or more peptides of the polypeptide with one or more acidic moiety reagents.

The kits of the present invention may be adapted to a mass spectrometer in a similar fashion as the sample holder described in, for example, Patterson, U.S. Patent No. 5,827,659, assigned to PerSeptive Biosystems, Inc., issued October 27, 1998.

5 Optionally, the kits may further comprise one or more verification peptides to test, for example, the accuracy of the mass spectrometric technique. Reference mass spectral data may also be optionally be included.

10 The acidic moiety reagents which may be included in the kits are described above.

Especially preferred means for derivatizing include those which allow convenient derivatization by the analyst or any other person interested in obtaining the derivatized polypeptide or peptides. A particularly preferred means for derivatizing comprises one or more containment devices to contain, for example, the acidic moiety reagent and ultimately the polypeptide / peptides of interest.

15 Suitable containment devices include, for example, vials, tubes, pipette tips, plates, sample holders, and multi-well plates. Optional convenience is provided wherein the acidic moiety reagent resides within the containment device so that it need not be added by the analyst. For example, the acidic moiety reagent may reside on the inside of a pipette tip and activated as the polypeptide or peptides are pulled into the tip with a suitable buffer. The containment device 20 is most preferably disposable, but need not be.

25 The acidic moiety reagent may also be bound to a solid support. For example, the reagent may be support-bound inside a pipette tip. The polypeptide or peptides of interest may be taken up in an appropriate buffer system and repeatedly drawn over the bound reagent. After reaction, an appropriate quantity of the derivatized polypeptide or peptides may be loaded directly onto the MALDI mass spectrometry sample stage, or injected into an electrospray ionization mass spectrometry device.

30 One or more buffer systems used to facilitate derivatization may also be included in the kits of the present invention. The buffer system appropriate for inclusion is dependent upon the acidic moiety reagent included. Examples of preferred buffer systems are disclosed in the derivatization examples above. Particularly preferred buffer systems include, but are not limited to, tertiary amine solutions (both aqueous and non-aqueous (for example, solutions in tetrahydrofuran)) and neat tertiary amines. Particularly preferred tertiary amines include trimethylamine, triethylamine, and diisopropylethylamine.

35 The kits of the present invention may also comprise one or more digestion aids such as those described herein above. Digestion aids may be chemical or enzymatic. For example,

trypsin, endoproteinase Lys C, endoproteinase Arg C, and / or chymotrypsin, preferably, trypsin, endoproteinase Lys C, and / or endoproteinase Arg C, and most preferably trypsin may be included as a digestion aid. Chemical digestion aids, such as cyanogen bromide, may also be included herein.

## WHAT IS CLAIMED IS:

1. A method of determining the amino acid sequence of a polypeptide characterized in that it comprises:
  - (a) derivatizing the N-terminus of the polypeptide or the N-termini of one or more peptides of the polypeptide with one or more acidic moieties having pK<sub>a</sub>s of less than 2, preferably less than 0, more preferably less than -2 when coupled with the polypeptide or peptides, to provide one or more derivatized analytes;
  - (b) analyzing one or more derivatized analytes using a mass spectrometric technique to provide a fragmentation pattern, preferably the fragmentation pattern is substantially free of a-ions and b-ions; and
  - (c) interpreting the fragmentation pattern.
2. A method according to Claim 1 characterized in that the mass spectrometric technique is MALDI PSD mass spectrometry, preferably positive ion mode PSD MALDI; or electrospray ionization tandem mass spectrometry, preferably tandem electrospray ionization mass spectrometry.
3. A method according to Claim 1 or 2 characterized in that interpretation of the fragmentation pattern comprises using a commercially available software program or database.
4. A method according to any of Claims 1-3 characterized in that the polypeptide is a synthetic polypeptide.
5. A method according to any of Claims 1-4 characterized in that the peptides of the polypeptide are produced by digestion, preferably the digestion is chemical digestion, more preferably the chemical digestion is cyanogen bromide digestion.
6. A method according to Claim 5 characterized in that the digestion is enzymatic digestion, preferably the enzymatic digestion is selected from endoproteinase Lys C digestion, endoproteinase Arg C digestion, tryptic digestion, and chymotryptic digestion.

7. A method according to any of Claims 1-6 characterized in that the acidic moiety is one or more sulfonic acids or a disulfonic acid derivative, preferably the acidic moiety is a 2-sulfoacetyl moiety, a 3-sulfopropionoyl moiety, or a 2-sulfobenzoyl moiety.
8. A kit for use in determining the amino acid sequence of a polypeptide characterized in that it comprises:
  - (a) one or more acidic moiety reagents providing one or more acidic moieties having pK<sub>a</sub>s of less than 2 when coupled with the polypeptide or one or more peptides of the polypeptide; and
  - (b) means for derivatizing the N-terminus of the polypeptide or the N-termini of one or more peptides of the polypeptide with one or more acidic moiety reagents.
9. A kit according to Claim 8 characterized in that the means for derivatizing comprises one or more containment devices, preferably the acidic moiety reagent resides within the containment devices; preferably the means for derivatizing further comprises a buffer system.
10. A kit according to Claim 8 or 9 characterized in that it further comprises one or more digestion aids.

## SEQUENCE LISTING

<110> Keough, Thomas W.  
Youngquist, Robert S.

5 <120> Methods and Kits for Sequencing Polypeptides

<130> Methods/Kits for Sequencing Polypeptides

10 <140> 7379P2  
<141> 1999-09-29

<160> 9

15 <170> PatentIn Ver. 2.0

<210> 1  
<211> 8  
<212> PRT

20 <213> synthetic construct

<400> 1  
Ala Ser His Leu Gly Leu Ala Arg  
1 5

25

<210> 2  
<211> 9  
<212> PRT

30 <213> synthetic construct

<400> 2  
Cys Asp Pro Gly Tyr Ile Gly Ser Arg  
1 5

35

<210> 3  
<211> 6  
<212> PRT

40 <213> synthetic construct

<400> 3  
His Leu Gly Leu Ala Arg  
1 5

45

<210> 4  
<211> 30  
<212> PRT

50 <213> bovine insulin

<400> 4

Phe Val Asn Gln His Leu Xaa Gly Ser His Leu Val Glu Ala Leu Tyr  
1 5 10 15

Leu Val Xaa Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala  
5 20 25 30

10 <210> 5  
<211> 14  
<212> PRT  
<213> pre adipocytes

15 <400> 5  
Phe Val Thr Val Gln Thr Ile Ser Gly Thr Gly Ala Leu Arg  
1 5 10

20 <210> 6  
<211> 16  
<212> PRT  
<213> pre adipocytes

25 <400> 6  
Ile Leu Ile Arg Pro Leu Tyr Ser Asn Pro Pro Leu Asn Gly Ala Arg  
1 5 10 15

30 <210> 7  
<211> 7  
<212> PRT  
<213> rat lymph

35 <400> 7  
Val Val Leu His Pro Glu Arg  
1 5

40 <210> 8  
<211> 5  
<212> PRT  
<213> rat lymph

45 <400> 8  
Asn Val Asn Phe Arg  
1 5

50 <210> 9  
<211> 21  
<212> PRT  
<213> Unknown

55 <220>  
<223> Description of Unknown Organism: Peptide

60 <400> 9  
Gly Val Leu Val Val Ala Ala Ser Gly Asn Ser Gly Ala Gly Ser Ile  
1 5 10 15

60 Ser Tyr Pro Ala Arg  
20

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
27 July 2000 (27.07.2000)

PCT

(10) International Publication Number  
WO 00/43792 A3

(51) International Patent Classification<sup>7</sup>: G01N 33/68 (81) Designated States (*national*): AE, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US00/00790

(22) International Filing Date: 12 January 2000 (12.01.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/116,502 20 January 1999 (20.01.1999) US  
60/156,677 29 September 1999 (29.09.1999) US

(71) Applicant (*for all designated States except US*): THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): KEOUGH, Thomas, Woods [US/US]; 9896 Barnsley Court, Cincinnati, OH 45242 (US). YOUNGQUIST, Robert, Scott [US/US]; 8511 Charleston Knoll Court, Mason, OH 45040 (US).


(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

— *With international search report.*(88) Date of publication of the international search report:  
30 November 2000

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 00/43792 A3

(54) Title: METHODS AND KITS FOR SEQUENCING POLYPEPTIDES

(57) Abstract: The present disclosure provides methods and kits which are useful for sequencing polypeptides. The methods involve derivatization of the N-terminus of the polypeptide or peptides thereof. Mass spectral analysis of one or more of the resulting derivatized analytes provides spectra which are readily interpreted through the use of techniques well-known to the ordinarily skilled artisan. The present disclosure also describes kits which enhance convenient performance of the methods.

# INTERNATIONAL SEARCH REPORT

Intern	nal Application No
PCT/US 00/00790	

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BEILSTEIN Data, EPO-Internal, CHEM ABS Data, WPI Data, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>COX K A ET AL: "Role of the Site of Protonation in the Low-Energy Decompositions of Gas-Phase Peptide Ions" JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, US, ELSEVIER SCIENCE INC, vol. 7, no. 6, 1 June 1996 (1996-06-01), pages 522-531, XP004052038 ISSN: 1044-0305 cited in the application page 523, column 2, line 13, paragraph 2 - line 24</p> <p>---</p> <p style="text-align: center;">-/-</p>	1-10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

3 July 2000

Date of mailing of the international search report

17/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hart-Davis, J

## INTERNATIONAL SEARCH REPORT

Int. Appl. No.

PCT/US 00/00790

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NAKANISHI T ET AL: "Electrospray Ionization—Tandem Mass Spectrometry Analysis of Peptides Derived by Enzymatic Digestion of Oxidized Globin Subunits: An Improved Method to Determine Amino Acid Substitution in the Hemoglobin 'Core'" JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, US, ELSEVIER SCIENCE INC, vol. 7, no. 10, 1 October 1996 (1996-10-01), pages 1040-1049, XP004070144 ISSN: 1044-0305 the whole document ---	1-10
A	ROTH K.D.W., HUANG Z.-H., SADAGOPAN N., WATSON J.T.: "Charge derivatization of peptides for analysis by mass spectrometry" MASS SPECTROM. REV., vol. 17, 1998, page 255 XP000922702 the whole document ---	1-10
A	HUANG Z.-H., WU J., ROTH K.D.W., YANG Y., GAGE D.A., WATSON J.T.: "A picomole-scale method for charge derivatization of peptides for sequence analysis by mass spectrometry" ANALYTICAL CHEMISTRY, vol. 69, 1997, pages 137-144, XP002141708 the whole document ---	1-10
P, X	KEOUGH, T.; YOUNGQUIST, R. S.; LACEY, M. P.: "A method for high-sensitivity peptide sequencing using postsource decay matrix-assisted laser desorption ionization mass spectrometry" PROC. NATL. ACAD. SCI. U. S. A., vol. 96, June 1999 (1999-06), pages 7131-7136, XP002141709 the whole document ---	1-10
T	DATABASE CHEMICAL ABSTRACTS 'Online! American Chemical Society (via STN, Karlsruhe); Accession Number 2000:391605 (CAPLUS), BAUER, MARK D.; SUN, YIPING; KEOUGH, THOMAS ; LACEY, MARTIN P.: "Sequencing of sulfonic acid derivatized peptides by electrospray mass spectrometry" XP002141711 abstract & RAPID COMMUN. MASS SPECTROM. , vol. 14, no. 10, 2000, pages 924-929, --- -/-	1-10

## INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/00790

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	<p>HUANG ZHI-HENG; SHEN TUNLI; WU JIANG; GAGE DOUGLAS A; WATSON J THROCK: "Protein sequencing by matrix-assisted laser desorption ionization-postsource decay-mass spectrometry analysis of the N-Tris(2,4,6-trimethoxyphenyl)phosphine-acetylated tryptic digests" ANALYTICAL BIOCHEMISTRY, vol. 268, 15 March 1999 (1999-03-15), pages 305-317, XP002141710 the whole document</p> <p>---</p> <p>CHEN X ET AL: "Isotope Edited Product Ion Assignment by alpha-N Labeling of Peptides with 'H3(50%)!2,4-Dinitrofluorobenzene'" JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, US, ELSEVIER SCIENCE INC., NEW YORK, NY, vol. 10, no. 5, May 1999 (1999-05), pages 448-452, XP004164485 ISSN: 1044-0305 the whole document</p> <p>-----</p>	1-10
P,A		1-10



#### RELATED PROCEEDINGS APPENDIX

There are no other appeals or interferences related to the instant appeal.